Similar results have been obtained by Wang et al., who vaccinated GBM patients with personalized TAA-pulsed DC combined with low-dose cyclophosphamide, poly(IC), imiquimod, and anti-PD-1 antibody, which induced antigen-specific CD4+ and CD8+ T-cell responses, which were associated with a favorable outcome when compared with the respective monotherapies (86). The gene discussed is CD8A; the disease is glioblastoma.